425: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance Amidst Mallinckrodt Merger

Endo reaffirms its 2025 financial guidance, projecting revenues between $1,775 and $1,860 million and adjusted EBITDA between $620 and $650 million, while advancing its merger with Mallinckrodt.

Summary

• Endo reported first-quarter 2025 financial results, with total revenues of $393 million, a 6% decrease compared to $420 million in the first quarter of 2024.
• The decrease in revenue was primarily due to competitive pressure in the Sterile Injectables and Generic Pharmaceuticals segments, offset by growth in Branded Pharmaceuticals.
• Net loss for the quarter was $129 million, compared to $154 million in the same period last year, driven by decreased expenses related to Chapter 11 reorganization.
• Adjusted EBITDA was $99 million, down from $146 million in the prior year, due to decreased revenues and investments in the Sterile Injectables manufacturing network and R&D.
• XIAFLEX revenues grew by 7% to $121 million, driven by volume growth.
• Endo reaffirms its full-year 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million.
• The merger with Mallinckrodt is expected to close in the second half of 2025.
• Endo had $370 million in unrestricted cash and cash equivalents as of March 31, 2025, compared to $387 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company reaffirms its guidance and highlights positive performance in certain segments like XIAFLEX, overall revenue and EBITDA are down. The merger announcement adds a layer of complexity and uncertainty.

Positives

• XIAFLEX revenues increased by 7% to $121 million, driven by volume growth.
• Net loss improved to $129 million from $154 million in Q1 2024.
• Endo reaffirms 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million.
• SUPPRELIN LA revenues increased 36% year-over-year.
• Lidocaine patch 5% revenues increased 16% year-over-year.

Negatives

• Total revenues decreased by 6% to $393 million compared to Q1 2024.
• Adjusted EBITDA decreased to $99 million from $146 million year-over-year.
• Sterile Injectables segment revenues decreased by 27% due to competitive pressure on VASOSTRICT and ADRENALIN vials.
• Generic Pharmaceuticals segment revenues decreased by 4% due to competitive pressure.
• International Pharmaceuticals segment revenues decreased by 24% due to the expiration of a license to distribute a product.
• Adjusted Net Income decreased to $24 million from $131 million year-over-year.

Risks

• Competitive pressure in the Sterile Injectables and Generic Pharmaceuticals segments.
• Potential delays or failure to obtain regulatory and shareholder approvals for the Mallinckrodt merger.
• Uncertainty regarding the planned separation of the combined company's generic pharmaceuticals and sterile injectables businesses.
• Impact of future tariffs and trade policy changes.
• Dependence on third parties for goods and services.
• Litigation risks.
• Supply chain issues.

Future Outlook

Endo reaffirms its full-year 2025 financial guidance, projecting revenues between $1,775 and $1,860 million and adjusted EBITDA between $620 and $650 million. The combination with Mallinckrodt is expected to close in the second half of 2025, subject to approvals and customary closing conditions.

Management Comments

• As we advance Endos transformation with two major transactions announced in March, the Company remains focused on executing our growth drivers, as evidenced by strong XIAFLEX performance in our Branded Pharmaceuticals business and the advancement of our Sterile Injectables pipeline, said Scott Hirsch, Endos Interim CEO.
• As a result of our first-quarter results, which met internal expectations across all segments, we are reaffirming our full-year 2025 earnings guidance.

Industry Context

The pharmaceutical industry is facing increasing competitive pressures, particularly in the generics and sterile injectables segments. Endo's strategic move to merge with Mallinckrodt aims to create a more diversified and scaled pharmaceutical leader, better positioned to navigate these challenges. Divesting the International Pharmaceuticals business allows Endo to focus on its core strengths and strategic priorities.

Comparison to Industry Standards

• Comparing Endo's performance to companies like Teva Pharmaceuticals and Mylan (now Viatris), which also operate in the generic and specialty pharmaceutical spaces, reveals similar challenges in revenue growth due to pricing pressures and competition.
• Endo's adjusted EBITDA margin of approximately 25% (based on Q1 2025 results) is within the range of other specialty pharmaceutical companies, but lower than some of its peers with more diversified portfolios.
• The planned merger with Mallinckrodt is a strategic move similar to other industry consolidations aimed at achieving economies of scale and diversifying product offerings, such as the acquisition of Allergan by AbbVie.

Stakeholder Impact

• Shareholders will be impacted by the merger with Mallinckrodt, receiving cash and equity in the combined company.
• Employees may experience changes due to the integration of Endo and Mallinckrodt.
• Customers will continue to have access to Endo's pharmaceutical products.
• Suppliers may see changes in procurement and supply chain management as a result of the merger.
• Creditors will be affected by the financial restructuring and the terms of the merger agreement.

Next Steps

• Obtain shareholder and regulatory approvals for the Mallinckrodt merger.
• Close the divestiture of the International Pharmaceuticals business.
• Integrate Endo and Mallinckrodt post-merger.
• Potentially separate the combined company's generic pharmaceuticals and sterile injectables businesses.
• Continue to advance the Sterile Injectables pipeline.

Key Dates

Keywords

Endo, Mallinckrodt, Merger, Financial Results, XIAFLEX, Sterile Injectables, Generic Pharmaceuticals, EBITDA, Revenue, Guidance